Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen +7 more
wiley +1 more source
Late Anthracycline Cardiotoxicity Mimicking Arrhythmogenic Cardiomyopathy in a Young Adult. [PDF]
Chedid M +4 more
europepmc +1 more source
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu +9 more
wiley +1 more source
Spatiotemporal Analysis of Mortality from Cardiomyopathies in Brazil between 2001 and 2021. [PDF]
Kubrusly LF +9 more
europepmc +1 more source
FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran +10 more
wiley +1 more source
Coexistence of Hypertrophic Cardiomyopathy and Hereditary Transthyretin Amyloid Cardiomyopathy. [PDF]
Coderre R +9 more
europepmc +1 more source
Genotype-Phenotype Discordance in Cardiomyopathies: Pathophysiology, Clinical Expression, and Therapeutic Considerations. [PDF]
Nazir A +9 more
europepmc +1 more source
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher +12 more
wiley +1 more source
Can Systemic Sarcoidosis and Genetic Cardiomyopathy Coexist? [PDF]
Wagle AA +5 more
europepmc +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source

